Cellceutix Corporation (CTIX)
-OTC BB 1.99 May 23, 3:59PM EDT|Pre-Market
:
NaN
| Prev Close: | 1.99 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | -0.75 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.50 - 2.47 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 208,514 |
|---|
| Market Cap: | 190.29M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.04 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 3 Small Cap Cancer Stocks With Upcoming Catalystsat Seeking Alpha(Mon, May 20)
- CELLCEUTIX CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, May 20)
- Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrivedat Seeking Alpha(Thu, May 9)
- Potential 200% Return With Cellceutixat Seeking Alpha(Mon, Apr 22)
- Coach Jim Boeheim Putting Up His Best Defense Against Michigan... and CancerMarketwired(Fri, Apr 5)
- Cellceutix Selected for Poster Presentation on Kevetrin at 2013 ASCO MeetingMarketwired(Mon, Apr 1)
- An Interview With Leo Ehrlich, Cellceutix CEOat Seeking Alpha(Thu, Mar 14)
- Cellceutix Plans for Future Trials Aimed at the Latest Initiatives of 'Breakthrough' Designation by the Food and Drug AdministrationMarketwired(Mon, Mar 11)
- CELLCEUTIX CORP Files SEC form 8-K, Unregistered Sale of Equity SecuritiesEDGAR Online(Fri, Mar 8)
- CELLCEUTIX CORP Files SEC form 8-K, Regulation FD DisclosureEDGAR Online(Mon, Mar 4)
- Cellceutix Signs With Leading Cancer Center for Licensing New DrugMarketwired(Mon, Mar 4)
- Cellceutix - A Biotech To Consider For 2013at Seeking Alpha(Sat, Mar 2)
- Cellceutix Reports on Kevetrin Clinical Trials and Prurisol ManufacturingMarketwired(Mon, Feb 25)
- CELLCEUTIX CORP FinancialsEDGAR Online Financials(Thu, Feb 21)
- CELLCEUTIX CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, Feb 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cellceutix Corporation, a development stage biopharmaceutical company, engages in the discovery and development of small molecule drugs to treat diseases primarily in the areas of cancer and inflammatory disease.
View More 
0.08%